Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Preferences for multigene panel testing for hereditary breast cancer risk among ethnically diverse BRCA-uninformative families.

Vicuña B, Delaney HD, Flores KG, Ballinger L, Royce M, Dayao Z, Pal T, Kinney AY.

J Community Genet. 2018 Jan;9(1):81-92. doi: 10.1007/s12687-017-0322-8. Epub 2017 Oct 2.

2.

Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol.

Katapodi MC, Viassolo V, Caiata-Zufferey M, Nikolaidis C, Bührer-Landolt R, Buerki N, Graffeo R, Horváth HC, Kurzeder C, Rabaglio M, Scharfe M, Urech C, Erlanger TE, Probst-Hensch N, Heinimann K, Heinzelmann-Schwarz V, Pagani O, Chappuis PO.

JMIR Res Protoc. 2017 Sep 20;6(9):e184. doi: 10.2196/resprot.8138.

3.

Factors Associated with Interest in Gene-Panel Testing and Risk Communication Preferences in Women from BRCA1/2 Negative Families.

Flores KG, Steffen LE, McLouth CJ, Vicuña BE, Gammon A, Kohlmann W, Vigil L, Dayao ZR, Royce ME, Kinney AY.

J Genet Couns. 2017 Jun;26(3):480-490. doi: 10.1007/s10897-016-0001-7. Epub 2016 Aug 6.

PMID:
27496122
4.

Understanding the Needs of Young Women Regarding Breast Cancer Risk Assessment and Genetic Testing: Convergence and Divergence among Patient-Counselor Perceptions and the Promise of Peer Support.

Evans C, Hamilton RJ, Tercyak KP, Peshkin BN, Rabemananjara K, Isaacs C, O'Neill SC.

Healthcare (Basel). 2016 Jun 28;4(3). pii: E35. doi: 10.3390/healthcare4030035.

5.

Psychosocial telephone counseling for survivors of cervical cancer: results of a randomized biobehavioral trial.

Wenzel L, Osann K, Hsieh S, Tucker JA, Monk BJ, Nelson EL.

J Clin Oncol. 2015 Apr 1;33(10):1171-9. doi: 10.1200/JCO.2014.57.4079. Epub 2015 Feb 23.

6.

Intervention completion rates among African Americans in a randomized effectiveness trial for diet and physical activity changes.

Halbert CH, Bellamy S, Briggs V, Bowman M, Delmoor E, Johnson JC, Kumanyika S, Melvin C, Purnell J, Rogers R, Weathers B.

Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1306-13. doi: 10.1158/1055-9965.EPI-13-1064. Epub 2014 Apr 22.

7.

Long-term satisfaction and quality of life following risk reducing surgery in BRCA1/2 mutation carriers.

Hooker GW, King L, Vanhusen L, Graves K, Peshkin BN, Isaacs C, Taylor KL, Poggi E, Schwartz MD.

Hered Cancer Clin Pract. 2014 Apr 2;12(1):9. doi: 10.1186/1897-4287-12-9.

8.

Communication and technology in genetic counseling for familial cancer.

Lynch HT, Snyder C, Stacey M, Olson B, Peterson SK, Buxbaum S, Shaw T, Lynch PM.

Clin Genet. 2014 Mar;85(3):213-22. doi: 10.1111/cge.12317. Epub 2013 Dec 20. Review.

9.

Seeking balance: decision support needs of women without cancer and a deleterious BRCA1 or BRCA2 mutation.

Underhill ML, Crotser CB.

J Genet Couns. 2014 Jun;23(3):350-62. doi: 10.1007/s10897-013-9667-2. Epub 2013 Nov 22.

10.

Communication of genetic test results to family and health-care providers following disclosure of research results.

Graves KD, Sinicrope PS, Esplen MJ, Peterson SK, Patten CA, Lowery J, Sinicrope FA, Nigon SK, Borgen J, Gorin SS, Keogh LA, Lindor NM; Behavioral Working Group of the Colon Cancer Family Registry.

Genet Med. 2014 Apr;16(4):294-301. doi: 10.1038/gim.2013.137. Epub 2013 Oct 3.

11.

Randomized controlled trial to test a computerized psychosocial cancer assessment and referral program: methods and research design.

O'Hea EL, Cutillo A, Dietzen L, Harralson T, Grissom G, Person S, Boudreaux ED.

Contemp Clin Trials. 2013 May;35(1):15-24. doi: 10.1016/j.cct.2013.02.001. Epub 2013 Feb 7.

12.

Primary-care physicians' access to genetic specialists: an impediment to the routine use of genomic medicine?

Haga SB, Burke W, Agans R.

Genet Med. 2013 Jul;15(7):513-4. doi: 10.1038/gim.2012.168. Epub 2013 Jan 10. No abstract available.

13.

Biopsychological stress factors in BRCA mutation carriers.

Wenzel L, Osann K, Lester J, Kurz R, Hsieh S, Nelson EL, Karlan B.

Psychosomatics. 2012 Nov-Dec;53(6):582-90. doi: 10.1016/j.psym.2012.06.007. Erratum in: Psychosomatics. 2015 Jan-Feb;56(1):106.

14.

Effectiveness of a condensed protocol for disclosing APOE genotype and providing risk education for Alzheimer disease.

Roberts JS, Chen CA, Uhlmann WR, Green RC.

Genet Med. 2012 Aug;14(8):742-8. doi: 10.1038/gim.2012.37. Epub 2012 Apr 12.

15.

Long-term psychosocial outcomes of BRCA1/BRCA2 testing: differences across affected status and risk-reducing surgery choice.

Graves KD, Vegella P, Poggi EA, Peshkin BN, Tong A, Isaacs C, Finch C, Kelly S, Taylor KL, Luta G, Schwartz MD.

Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):445-55. doi: 10.1158/1055-9965.EPI-11-0991. Epub 2012 Feb 10.

16.

Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: does time heal women's concerns?

Halbert CH, Stopfer JE, McDonald J, Weathers B, Collier A, Troxel AB, Domchek S.

J Clin Oncol. 2011 Nov 10;29(32):4302-6. doi: 10.1200/JCO.2010.33.1561. Epub 2011 Oct 11.

17.

Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.

Schwartz MD, Isaacs C, Graves KD, Poggi E, Peshkin BN, Gell C, Finch C, Kelly S, Taylor KL, Perley L.

Cancer. 2012 Jan 15;118(2):510-7. doi: 10.1002/cncr.26294. Epub 2011 Jun 29.

18.

BRCA1/2 genetic testing uptake and psychosocial outcomes in men.

Graves KD, Gatammah R, Peshkin BN, Krieger A, Gell C, Valdimarsdottir HB, Schwartz MD.

Fam Cancer. 2011 Jun;10(2):213-23. doi: 10.1007/s10689-011-9425-2.

Supplemental Content

Support Center